

Claims

1. A heterodimeric antibody comprising the HC1 (Fab-Fc), the HC2 (scFv-Fc) and the LC of Figure 136C.
2. The heterodimeric antibody of claim 1 consisting of the HC1 (Fab-Fc), the HC2 (scFv-Fc) and the LC of Figure 136C.
3. A nucleic acid composition comprising three nucleic acids encoding the heterodimeric antibody of claim 1 or claim 2.
4. An expression vector composition comprising three nucleic acids encoding the heterodimeric antibody of claim 1 or claim 2.
5. A host cell comprising the nucleic acid composition of claim 3.
6. A host cell comprising the expression vector composition of claim 4.
7. A method of making the heterodimeric antibody of claim 1 or claim 2 comprising culturing the host cell of claim 5 or claim 6 under conditions wherein said antibody is expressed, and recovering said antibody.
8. A heterodimeric antibody of claim 1 or claim 2 for use in treating cancer.
9. Use of a heterodimeric antibody according to claim 1 or claim 2, in the manufacture of a medicament for the treatment of a hematopoietic cancer.
10. The use according to claim 9, wherein said hematopoietic cancer is a B cell lymphoma or leukemia.
11. The use according to claim 10, wherein said B cell lymphoma or leukemia is selected from the group consisting of non-Hodgkin's lymphoma (NHL), Burkitt's lymphoma (BL), multiple myeloma (MM), B chronic lymphocytic leukemia (B-CLL), B and T acute lymphocytic leukemia (ALL), T cell lymphoma (TCL), acute myeloid leukemia (AML), hairy cell leukemia (HCL), Hodgkin's Lymphoma (HL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma, and chronic myeloid leukemia (CML).